Skip to main content

Table 1 Formulations of polypill available for prescription, and recommended indications

From: Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk

Clinical history Intervention group
Coronary heart disease Formulation 1*
Cerebrovascular disease Formulation 2**
Both or other athero-thrombotic vascular disease Either Formulation 1* or 2**
>15% 5-year CVD risk, but without established CVD Formulation 2**
  1. *Polypill with aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, atenolol 50 mg
  2. **Polypill with aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg